Behavioral effects of neuropeptides in rodent models of depression and anxiety

Depression: a new animal model sensitive to antidepressant treatments

PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451

Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and β-Endorphin

Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965

Characterization of a 41-Residue Ovine Hypothalamic Peptide that Stimulates Secretion of Corticotropin and β-Endorphin

Vale, W., Spiess, J., RIVIER, C. L., & Rivier, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904

Behavioural despair in rats: A new model sensitive to antidepressant treatments

Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90118-8 · Cited by 3,138

Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress

Heinrichs, M., Baumgartner, T., Kirschbaum, C., & Ehlert, U. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00465-7 · Cited by 2,091

Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant

Willner, P., Towell, A., Sampson, D., Sophokleous, S., & Muscat, R. (1987) · Psychopharmacology · doi:10.1007/bf00187257 · Cited by 1,993

The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice

Cryan, J. F., Mombereau, C., & Vassout, A. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.009 · Cited by 1,674

Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans

Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639

Assessing antidepressant activity in rodents: recent developments and future needs

Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551

Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor

Vaughan, J. M., Donaldson, C. J., Bittencourt, J. C., Perrin, M. H., Lewis, K., Sutton, S. W., Chan, R. K. W., Turnbull, A. V., Lovejoy, D. A., RIVIER, C. L., et al. (1995) · Nature · doi:10.1038/378287a0 · Cited by 1,479

The role of corticotropin-releasing factor in depression and anxiety disorders

Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378

Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?

Dunn, A. J., & Berridge, C. W. (1990) · Brain Research Reviews · doi:10.1016/0165-0173(90)90012-d · Cited by 1,352

A potent and selective endogenous agonist for the µ-opiate receptor

Zadina, J. E., Hackler, L., Ge, L.-J., & Kastin, A. J. (1997) · Nature · doi:10.1038/386499a0 · Cited by 1,309

Fear and anxiety: Animal models and human cognitive psychophysiology

Lang, P. J., Davis, M., & Öhman, A. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00343-8 · Cited by 1,162

Chronic mild stress-induced anhedonia: A realistic animal model of depression

Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160

Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test

Cryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,138

Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors

Kramer, M. S., Cutler, N. R., Feighner, J. P., Shrivastava, R. K., Carman, J. S., Sramek, J. J., Reines, S. A., Liu, G. F., Snavely, D. B., Wyatt-Knowles, E. S., et al. (1998) · Science · doi:10.1126/science.281.5383.1640 · Cited by 1,071

Is the forced swimming test a suitable model for revealing antidepressant activity?

Borsini, F., & Meli, A. (1988) · Psychopharmacology · doi:10.1007/bf00176837 · Cited by 1,053

Anxiety, defence and the elevated plus-maze.

Rodgers, R., & Dalvi, A. (1997) · Neuroscience and Biobehavioral Reviews · doi:10.1016/s0149-7634(96)00058-9 · Cited by 1,028

Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor

Lewis, K., Li, C., Perrin, M. H., Blount, A., Kunitake, K., Donaldson, C., Vaughan, J., Reyes, T. M., Gulyas, J., Fischer, W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121165198 · Cited by 925

Ethologically-based animal models of anxiety disorders.

Lister, R. (1990) · Pharmacology and Therapeutics · doi:10.1016/0163-7258(90)90021-s · Cited by 894

Urocortin II: A Member of the Corticotropin-Releasing Factor (CRF) Neuropeptide Family that Is Selectively Bound by Type 2 CRF Receptors

Reyes, T. M., Lewis, K., Perrin, M. H., Kunitake, K. S., Vaughan, J., Arias, C. A., Hogenesch, J. B., Gulyas, J., Rivier, J., Vale, W. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051626398 · Cited by 887

The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs

File, S. E. (1980) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(80)90012-6 · Cited by 820

CAN SOCIAL INTERACTION BE USED TO MEASURE ANXIETY?

File, S. E., & Hyde, J. R. G. (1978) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1978.tb07001.x · Cited by 808

Fear-potentiated startle: A neural and pharmacological analysis

Davis, M., Falls, W. A., Campeau, S., & Kim, M. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90102-v · Cited by 751

Brain oxytocin: A key regulator of emotional and social behaviours in both females and males

Neumann, I. D. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01726.x · Cited by 743

Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety

Shepherd, J. K., Grewal, S. S., Fletcher, A., Bill, D. J., & Dourish, C. T. (1994) · Psychopharmacology · doi:10.1007/bf02244871 · Cited by 739

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705

Anxiogenic stimuli in the elevated plus-maze

Treit, D., Menard, J., & Royan, C. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90492-c · Cited by 628

Neuropeptides — an overview

Hökfelt, T. G. M., Broberger, C., Xu, Q., Sergeyev, V., Ubink, R., & Diez, M. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00010-1 · Cited by 607

The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay

Beinfeld, M. C., Meyer, D., Eskay, R. L., Jensen, R. T., & Brownstein, M. (1981) · Brain Research · doi:10.1016/0006-8993(81)90031-7 · Cited by 551

Vasopressin: Behavioral roles of an “original” neuropeptide

Caldwell, H. K., Lee, H.-J., Macbeth, A. H., & Young, W. S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.10.007 · Cited by 504

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.

Hughes, J. W., Boden, P., Costall, B., Domeney, A. M., Kelly, E., Horwell, D. C., Hunter, J. C., Pinnock, R. D., & Woodruff, G. N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6728 · Cited by 501

Different data from different labs: Lessons from studies of gene–environment interaction

Wahłsten, D., Metten, P., Phillips, T. J., Boehm, S. L., Burkhart‐Kasch, S., Dorow, J. D., Doerksen, S., Downing, C., Fogarty, J., Rodd‐Henricks, K., et al. (2002) · Journal of Neurobiology · doi:10.1002/neu.10173 · Cited by 495

Animal model of depression: Pharmacological sensitivity of a hedonic deficit

Katz, R. J. (1982) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(82)90053-3 · Cited by 480

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471

Brain Oxytocin Inhibits Basal and Stress‐Induced Activity of the Hypothalamo‐Pituitary‐Adrenal Axis in Male and Female Rats: Partial Action Within the Paraventricular Nucleus

Neumann, Wigger, Torner, Holsboer, & Landgraf (2000) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.2000.00442.x · Cited by 452

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

Holmes, A., Heilig, M. A., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.09.011 · Cited by 405

Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2

Radulovic, J., Rühmann, A., Liepold, T., & Spiess, J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05016.1999 · Cited by 402

Brain oxytocin: differential inhibition of neuroendocrine stress responses and anxiety-related behaviour in virgin, pregnant and lactating rats

Neumann, I. D., Torner, L., & Wigger, A. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00433-9 · Cited by 402

Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models

Heilig, M. A., S�derpalm, B., Engel, J. A., & Widerl�v, E. (1989) · Psychopharmacology · doi:10.1007/bf00441953 · Cited by 390

Central CRH system in depression and anxiety — Evidence from clinical studies with CRH1 receptor antagonists

Holsboer, F., & Ising, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.032 · Cited by 380

CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

Schulz, D. W., Mansbach, R. S., Sprouse, J. S., Braselton, J. P., Collins, J. L., Corman, M. L., Dunaiskis, A. R., Faraci, S., Schmidt, A. W., Seeger, T., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10477 · Cited by 377

The Flinders sensitive line rats: a genetic animal model of depression

Overstreet, D. H. (1993) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80230-1 · Cited by 369

A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder

Guastella, A. J., Howard, A. L., Dadds, M. R., Mitchell, P., & Carson, D. S. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.01.005 · Cited by 366

Neuropeptides: opportunities for drug discovery

Hökfelt, T. G. M., Bartfai, T., & Bloom, F. E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00482-4 · Cited by 335

An Anxiolytic Action of Oxytocin is Enhanced by Estrogen in the Mouse

MCCARTHY, M. M., MCDONALD, C. H., BROOKS, P. J., & GOLDMAN, D. (1996) · Physiology & Behavior · doi:10.1016/s0031-9384(96)00212-0 · Cited by 328

Plasma oxytocin levels and anxiety in patients with major depression

Scantamburlo, G., Hansenne, M., Fuchs, S., Pitchot, W., Maréchal, P., Péqueux, C., Ansseau, M., & Legros, J. J. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.01.009 · Cited by 325

Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications

Ring, R. H., Malberg, J. E., Potestio, L., Ping, J., Boikess, S., Luo, B., Schechter, L. E., Rizzo, S., Rahman, Z., & Rosenzweig-Lipson, S. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0293-z · Cited by 319

Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression

van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306

The role of substance P in stress and anxiety responses

Ebner, K., & Singewald, N. (2006) · Amino Acids · doi:10.1007/s00726-006-0335-9 · Cited by 304

The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic

Blanchard, D. C., Griebel, G., & Blanchard, R. J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01276-7 · Cited by 295

Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder

Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.013 · Cited by 286

Prenatal stress generates deficits in rat social behavior: Reversal by oxytocin

Lee, P. R., Brady, D. L., Shapiro, R. A., Dorsa, D. M., & Koenig, J. I. (2007) · Brain Research · doi:10.1016/j.brainres.2007.04.042 · Cited by 270

Diazepam and flurazepam: Effects on conditioned fear as measured with the potentiated startle paradigm

Davis, M. (1979) · Psychopharmacology · doi:10.1007/bf00426027 · Cited by 263

Alterations in Central Neuropeptide Expression, Release, and Receptor Binding in Rats Bred for High Anxiety: Critical Role of Vasopressin

Wigger, A., Sánchez, M. M., Mathys, K. C., Ebner, K., Frank, E., Liu, D., Kresse, A. E., Neumann, I. D., Holsboer, F., Plotsky, P. M., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300290 · Cited by 263

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Kramer, M. S., Winokur, A., Kelsey, J. E., Preskorn, S., Rothschild, A. J., Snavely, D. B., Ghosh, K., Ball, W. A., Reines, S. A., Munjack, D. J., et al. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300260 · Cited by 254

A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression

Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071199 · Cited by 254

The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress**This research was supported by NIMH Grant MH-50479 and the Undergraduate Research Opportunities Program at the University of Colorado at Boulder.

Deak, T., Nguyen, K. T., Ehrlich, A. L., Watkins, L. R., Spencer, R. L., Maier, S. F., Licinio, J., Wong, M.-L., Chrousos, G. P., Webster, E., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6415 · Cited by 242

Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related behavior in rats

Ebner, K., Rupniak, N. M. J., Saria, A., & Singewald, N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400794101 · Cited by 225

Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin

Becker, C., Zeau, B., Rivat, C., Blugeot, A., Hamon, M., & Benoliel, J. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002097 · Cited by 225

Isolation and structure of hypothalamic MSH release-inhibiting hormone

Nair, R. M. G., Kastin, A. J., & Schally, A. V. (1971) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(71)80026-8 · Cited by 224

Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.

Singh, L., Lewis, A. S., Field, M. J., Hughes, J. W., & Woodruff, G. N. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1130 · Cited by 213

The Neuropeptide Y (NPY) Y1 Receptor Subtype Mediates NPY-induced Antidepressant-like Activity in the Mouse Forced Swimming Test

Redrobe, J. P. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00403-1 · Cited by 207

Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats.

Takahashi, L. K., Kalin, N. H., Burgt, J. A. V., & Sherman, J. E. (1989) · Behavioral Neuroscience · doi:10.1037//0735-7044.103.3.648 · Cited by 203

Oxytocin acts as an antidepressant in two animal models of depression

Arletti, R., & Bertolini, A. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90600-x · Cited by 203

Social Interaction Deficits Caused by Chronic Phencyclidine Administration are Reversed by Oxytocin

Lee, P. R., Brady, D. L., Shapiro, R. A., Dorsa, D. M., & Koenig, J. I. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300722 · Cited by 199

Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures

Broqua, P., Wettstein, J. G., Rocher, M. N., Gauthier-Martin, B., & Junien, J. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199504000-00001 · Cited by 198

Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats

Slattery, D. A., & Neumann, I. D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.038 · Cited by 195

Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist

Mansbach, R. S., Brooks, E. N., & Chen, Y. L. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00025-3 · Cited by 195

Pharmacological characterization of Endomorphin-1 and Endomorphin-2 in Mouse Brain

Goldberg, I. E., Rossi, G. C., Letchworth, S. R., Mathis, J. P., Ryan‐Moro, J. P., Leventhal, L., Su, W., Emmel, D. W., Bolan, E. A., & Pasternak, G. W. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37681-5 · Cited by 189

Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal 3 ) antagonists SNAP 37889 and SNAP 398299

Swanson, C. J., Blackburn, T. P., Zhang, X., Zheng, K., Xu, Q., Hökfelt, T. G. M., Wolinsky, T. D., Konkel, M. J., Chen, H., Zhong, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508970102 · Cited by 182

Regulation of Formation and Proposed Structure of the Factor Inhibiting the Release of Melanocyte-Stimulating Hormone

Celis, M. E., Taleisnik, S., & Walter, R. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.7.1428 · Cited by 181

Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats.

Takahashi, L. K., Kalin, N. H., Burgt, J. A. V., et al. (1989) · Behavioral Neuroscience · doi:10.1037/0735-7044.103.3.648 · Cited by 175

Septal vasopressin modulates anxiety-related behaviour in rats

Liebsch, G., Wotjak, C. T., Landgraf, R., & Engelmann, M. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)13069-x · Cited by 173

Recent advances in the neurobiology of anxiety disorders: Implications for novel therapeutics

Mathew, S. J., Price, R. B., & Charney, D. S. (2008) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30172 · Cited by 172

Is There a Future for Neuropeptide Receptor Ligands in the Treatment of Anxiety Disorders?

Griebel, G. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00041-2 · Cited by 171

Central Oxytocin Administration Reduces Stress-Induced Corticosterone Release and Anxiety Behavior in Rats1

Windle, R. J., Shanks, N., Lightman, S. L., & Ingram, C. D. (1997) · Endocrinology · doi:10.1210/en.138.7.2829 · Cited by 170

Urocortin, a novel neuropeptide with anxiogenic-like properties

Moreau, J., Kilpatrick, G. J., & Jenck, F. (1997) · Neuroreport · doi:10.1097/00001756-199705060-00027 · Cited by 170

Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice

Teixeira, R. M., Santos, A. R. S., Ribeiro, S. J., Calixto, J. Β., Rae, G. A., & de Lima, T. C. M. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00390-1 · Cited by 166

The vasopressin system — From antidiuresis to psychopathology

Frank, E., & Landgraf, R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.063 · Cited by 162

Localization of oxytocin receptor messenger ribonucleic acid in the rat brain.

Yoshimura, R., Kiyama, H., Kimura, T., Araki, T., Maeno, H., Tanizawa, O., & Tohyama, M. (1993) · Endocrinology · doi:10.1210/endo.133.3.8396014 · Cited by 161

The Role of CRF in Behavioral Aspects of Stress

Heinrichs, S. C., Menzaghi, F., Pich, E. M., Britton, K. T., & Koob, G. F. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44673.x · Cited by 160

Long-term neuroendocrine and behavioural effects of a single exposure to stress in adult animals

Armario, A., Escorihuela, R. M., & Nadal, R. A. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.04.003 · Cited by 160

The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats

Keck, M. E., Welt, T., Wigger, A., Renner, U., Engelmann, M., Holsboer, F., & Landgraf, R. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2000.01383.x · Cited by 154

Receptor Binding, Behavioral, and Electrophysiological Profiles of Nonpeptide Corticotropin-Releasing Factor Subtype 1 Receptor Antagonists CRA1000 and CRA1001

Okuyama, S., Chaki, S., Kawashima, N., Suzuki, Y., Ogawa, S., Nakazato, A., Kumagai, T., Okubo, T., & Tomisawa, K. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38220-5 · Cited by 152

Galanin – 25 years with a multitalented neuropeptide

Mitsukawa, K., Lü, X., & Bartfai, T. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8153-8 · Cited by 151

The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines

Millan, M. J., & Brocco, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01275-5 · Cited by 149

Brain Penetrance, Receptor Occupancy and Antistress In Vivo Efficacy of a Small Molecule Corticotropin Releasing Factor Type I Receptor Selective Antagonist

Heinrichs, S. C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00299-3 · Cited by 148

The role of CRH in behavioral responses to stress

Smagin, G. N., Heinrichs, S. C., & Dunn, A. J. (2001) · Peptides · doi:10.1016/s0196-9781(01)00384-9 · Cited by 148

Differential modulation of lateral septal vasopressin receptor blockade in spatial learning, social recognition, and anxiety-related behaviors in rats

Everts, H. G. J., & Koolhaas, J. M. (1999) · Behavioural Brain Research · doi:10.1016/s0166-4328(98)00004-7 · Cited by 147

The Effect of Lateral Septum Corticotropin-Releasing Factor Receptor 2 Activation on Anxiety Is Modulated by Stress

Henry, B., Vale, W., & Markou, A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1494-06.2006 · Cited by 147

Neuropeptide Y in the Amygdala Induces Long-Term Resilience to Stress-Induced Reductions in Social Responses But Not Hypothalamic–Adrenal–Pituitary Axis Activity or Hyperthermia

Sajdyk, T. J., Johnson, P. L., Leitermann, R. J., Fitz, S. D., Dietrich, A. D., Morin, M., Gehlert, D. R., Urban, J. H., & Shekhar, A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0659-07.2008 · Cited by 147

Neuropeptide Y (NPY) and depression: From animal studies to the human condition

Redrobe, J. P., Dumont, Y., & Quirion, R. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02159-8 · Cited by 146

Neuropeptide-Y exerts antidepressant-like effects in the forced swim test in rats

Stogner, K. A., & Holmes, P. V. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00800-6 · Cited by 144

Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist

Ring, R. H., Schechter, L. E., Leonard, S. K., Dwyer, J. M., Platt, B. J., Graf, R., Grauer, S. M., Pulicicchio, C. M., Resnick, L., Rahman, Z. U., et al. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.016 · Cited by 144

Biological actions of galanin

Crawley, J. N. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00083-n · Cited by 143

Anti-Stress Action of a Corticotropin-Releasing Factor Antagonist on Behavioral Reactivity to Stressors of Varying Type and Intensity

Heinrichs, S. C., Menzaghi, F., Pich, E. M., Baldwin, H. A., Rassnick, S., Britton, K. T., & Koob, G. F. (1994) · Neuropsychopharmacology · doi:10.1038/sj.npp.1380104 · Cited by 143

Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide

Valdez, G. R., Inoue, K., Koob, G. F., Rivier, J., Vale, W., & Zorrilla, E. P. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02707-5 · Cited by 143

Differences in intermale aggression are accompanied by opposite vasopressin release patterns within the septum in rats bred for low and high anxiety

Beiderbeck, D. I., Neumann, I. D., & Veenema, A. H. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05974.x · Cited by 142

Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist

Valdez, G. R., Zorrilla, E. P., Rivier, J., Vale, W., & Koob, G. F. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02971-8 · Cited by 140

Galanin: A Significant Role in Depression?

Weiss, J. M., Bonsall, R. W., Demetrikopoulos, M. K., Emery, M., & West, C. H. K. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10707.x · Cited by 139

Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects

Kunzel, H. E., Zobel, A. W., Nickel, T., Ackl, N., Uhr, M., Sonntag, A., Ising, M., & Holsboer, F. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00070-0 · Cited by 134

Antagonism of CRF2 receptors produces anxiolytic behavior in animal models of anxiety

Takahashi, L. K., Ho, S. P., Livanov, V., Graciani, N., & Arneric, S. P. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02405-2 · Cited by 132

A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus

Lü, X., Barr, A. M., Kinney, J. W., Sanna, P. P., Conti, B., Behrens, M. M., & Bartfai, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408891102 · Cited by 131

Behavioral reactivity to stress

Khoshbouei, H., Cecchi, M., Dove, S., Javors, M. A., & Morilak, D. A. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00683-9 · Cited by 130

Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation

Sørensen, G., Lindberg, C., Wörtwein, G., Bolwig, T. G., & Woldbye, D. P. D. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20200 · Cited by 124

Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test

Heilig, M. A., McLeod, S., Koob, G. K., & Britton, K. T. (1992) · Regulatory Peptides · doi:10.1016/0167-0115(92)90514-u · Cited by 123

Behavioral Characteristics of Rat Lines Selected for Differential Hypothermic Responses to Cholinergic or Serotonergic Agonists

Overstreet, D. H. (2002) · Behavior Genetics · doi:10.1023/a:1020262205227 · Cited by 122

Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models

Rotzinger, S., & Vaccarino, F. J. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0322 · Cited by 120

The Gerbil Elevated Plus-maze II Anxiolytic-like Effects of Selective Neurokinin NK1 Receptor Antagonists

Varty, G. B. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00313-5 · Cited by 120

Neuropeptide Y Produces Anxiety Via Y2-Type Receptors

Nakajima, M., Inui, A., Asakawa, A., Momose, K., Ueno, N., Teranishi, A., Baba, S., & Kasuga, M. (1998) · Peptides · doi:10.1016/s0196-9781(97)00298-2 · Cited by 119

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

Kramer, M. S., Cutler, N. R., Ballenger, J. C., Patterson, W. M., Mendels, J., Chenault, A., Shrivastava, R. K., Matzura‐Wolfe, D., Lines, C., & Reines, S. A. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00190-e · Cited by 117

The behavioural effects of corticotropin-releasing factor-related peptides in rats

Jones, D. N. C., Kortekaas, R., Slade, P. D., Middlemiss, D. N., & Hagan, J. J. (1998) · Psychopharmacology · doi:10.1007/s002130050654 · Cited by 115

The role of Corticotropin Releasing Factor in Depressive Illness: a Critical Review

Mitchell, A. J. (1998) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(97)00059-6 · Cited by 115

Anxiolytic-like action of centrally administered galanin

Bing, O., Møller, C. H., Engel, J. A., Söderpalm, B., & Heilig, M. A. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90846-d · Cited by 114

Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression

Overstreet, D. H., & Griebel, G. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.06.035 · Cited by 112

Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415

Stemmelin, J., Lukovic, L., Salome, N., & Griebel, G. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300562 · Cited by 112

Proteolytic conversion of arginine-vasopressin and oxytocin by brain synaptic membranes. Characterization of formed peptides and mechanisms of proteolysis.

Burbach, J. P. H., & Lebouille, J. L. M. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33011-4 · Cited by 111

Differential Role of Galanin Receptors in the Regulation of Depression-Like Behavior and Monoamine/Stress-Related Genes at the Cell Body Level

Kuteeva, E., Wardi, T., Lundström, L., Sollenberg, U. E., Langel, Ü., Hökfelt, T. G. M., & Ögren, S. O. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301660 · Cited by 110

Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor

Gehlert, D. R., Shekhar, A., Morin, S. M., Hipskind, P. A., Zink, C., Gackenheimer, S. L., Shaw, J., Fitz, S. D., & Sajdyk, T. J. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.12.030 · Cited by 110

Anxiogenic-Like Action of Galanin after Intra-Amygdala Administration in the Rat

Möller, C. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00102-x · Cited by 110

Galanin and Its Receptors in Neurological Disorders

Lundström, L., Elmquist, A., Bartfai, T., & Langel, Ü. (2005) · NeuroMolecular Medicine · doi:10.1385/nmm:7:1-2:157 · Cited by 110

Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice

Risbrough, V. B., Hauger, R. L., Pelleymounter, M. A., & Geyer, M. A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1535-6 · Cited by 107

Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice

Karlsson, R., Holmes, A., Heilig, M. A., & Crawley, J. N. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.12.009 · Cited by 105

A water lick conflict paradigm using drug experienced rats

Petersen, E. N., & Lassen, J. B. (1981) · Psychopharmacology · doi:10.1007/bf00432430 · Cited by 104

Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression

Overstreet, D. H., Keeney, A. J., & Hogg, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.04.010 · Cited by 104

Galanin, Galanin Receptor Subtypes and Depression-Like Behaviour

Kuteeva, E., Hökfelt, T. G. M., Wardi, T., & Ögren, S. O. (2010) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0346-0228-0_12 · Cited by 102

Melanocyte-Stimulating Hormone-Release Inhibiting Hormone as an Antidepressant

Ehrensing, R. H. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760070047007 · Cited by 96

Galanin receptors: Involvement in feeding, pain, depression and Alzheimer's disease

Kask, K., Berthold, M., & Bartfai, T. (1997) · Life Sciences · doi:10.1016/s0024-3205(96)00624-8 · Cited by 94

Anxiolytic Properties of the Selective, Non-peptidergic CRF1 Antagonists, CP154,526 and DMP695 A Comparison to Other Classes of Anxiolytic Agent

Millan, M. J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00244-5 · Cited by 94

Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze

Britton, K. T., Akwa, Y., Spina, M. G., & Koob, G. F. (2000) · Peptides · doi:10.1016/s0196-9781(99)00169-2 · Cited by 94

Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm

Kehne, J. H., Cassella, J. V., & Davis, M. (1988) · Psychopharmacology · doi:10.1007/bf00735872 · Cited by 93

Urocortin and the brain

Pan, W., & Kastin, A. J. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.10.008 · Cited by 92

Escape deficits induced by uncontrollable stress: Antagonism by dopamine and norepinephrine agonists

Anisman, H., Suissa, A., & Sklar, L. S. (1980) · Behavioral and Neural Biology · doi:10.1016/s0163-1047(80)93132-5 · Cited by 92

On the role of urocortin 1 in the non-preganglionic Edinger–Westphal nucleus in stress adaptation

Kozicz, T. (2007) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2007.04.005 · Cited by 92

Galanin – 25 years with a multitalented neuropeptide

Kuteeva, E., Hökfelt, T. G. M., Wardi, T., & Ögren, S. O. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8160-9 · Cited by 92

Vasopressin administration modulates anxiety-related behavior in rats

Appenrodt, E., Schnabel, R., & Schwarzberg, H. (1998) · Physiology & Behavior · doi:10.1016/s0031-9384(98)00119-x · Cited by 91

Enkephalin and other peptides reduce passiveness

Kastin, A. J., Scollan, E. L., Ehrensing, R. H., Schally, A. V., & Coy, D. H. (1978) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(78)90051-5 · Cited by 91

Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats

Wang, H., Wong, P. T. ‐., Spiess, J., & Zhu, Y. Z. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.05.008 · Cited by 89

Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats

Salomé, N., Stemmelin, J., Cohen, C., & Griebel, G. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0424-1 · Cited by 89

Modulatory Effects of Galanin in the Lateral Bed Nucleus of the Stria Terminalis on Behavioral and Neuroendocrine Responses to Acute Stress

Khoshbouei, H. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00424-9 · Cited by 88

Endomorphins have orexigenic and anxiolytic activities in mice

Asakawa, A., Inui, A., Momose, K., Ueno, N., Fujino, M., & Kasuga, M. (1998) · Neuroreport · doi:10.1097/00001756-199807130-00022 · Cited by 87

A comparison of anxiolytic and nonanxiolytic agents in the shock-probe/burying test for anxiolytics

Treit, D. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90151-7 · Cited by 86

Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression

Rh, E., & Aj, K. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.5.562 · Cited by 86

Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei

Beinfeld, M. C., & Palkovits, M. (1982) · Brain Research · doi:10.1016/0006-8993(82)90794-6 · Cited by 85

Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin‐releasing factor receptor type 1 and type 2 agonists

de Groote, L., Peñalva, R. G., Flachskamm, C., Reul, J. M. H. M., & Linthorst, A. C. E. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03164.x · Cited by 84

Teneurin proteins possess a carboxy terminal sequence with neuromodulatory activity

Wang, L., Rotzinger, S., Chawaf, A. A., Elias, C. F., Baršytė-Lovejoy, D., Qian, X., Wang, N.-C., Cristofaro, A. D., Belsham, D. D., Bittencourt, J. C., et al. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.10.019 · Cited by 83

Subtype-Selective Corticotropin-Releasing Factor Receptor Agonists Exert Contrasting, but Not Opposite, Effects on Anxiety-Related Behavior in Rats

Zhao, Y., Valdez, G. R., Fekete, É. M., Rivier, J., Vale, W. W., Rice, K. C., Weiss, F., & Zorrilla, E. P. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.123208 · Cited by 83

Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression

Hodgson, R. A., Higgins, G. A., Guthrie, D. H., Lu, S. X., Pond, A. J., Mullins, D. E., Guzzi, M. F., Parker, E. M., & Varty, G. B. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.12.021 · Cited by 82

Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety

Rezayat, M., Roohbakhsh, A., Zarrindast, M.-R., Massoudi, R., & Djahanguiri, B. (2005) · Physiology & Behavior · doi:10.1016/j.physbeh.2005.03.002 · Cited by 82

The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats

Papp, M., Vassout, A., & Gentsch, C. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00230-8 · Cited by 82

Activation of Amygdala CholecystokininBReceptors Potentiates the Acoustic Startle Response in the Rat

Frankland, P. W., Josselyn, S. A., Bradwejn, J., Vaccarino, F. J., & Yeomans, J. S. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01838.1997 · Cited by 81

Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats

Kokare, D. M., Dandekar, M. P., Chopde, C. T., & Subhedar, N. K. (2005) · Brain Research · doi:10.1016/j.brainres.2005.02.038 · Cited by 80

Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice

Nielsen, D. M., Carey, G. J., & Gold, L. H. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.091 · Cited by 80

Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats

Krase, W., Koch, M., & Schnitzler, H. (1994) · Behavioural Brain Research · doi:10.1016/0166-4328(94)90053-1 · Cited by 79

Anxiolytic-like effect of the selective Neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze

Bacchi, F., Mathé, A. A., Jiménez, P., Stasi, L. P., Arban, R., Gerrard, P. A., & Caberlotto, L. (2006) · Peptides · doi:10.1016/j.peptides.2006.07.020 · Cited by 79

A Double-Blind, Placebo-Controlled Study of a CCK-B Receptor Antagonist, CI-988, in Patients With Generalized Anxiety Disorder

Adams, J. B., Pyke, R. E., Costa, J., Cutler, N. R., Schweizer, E. E., Wilcox, C. S., Wisselink, P., Greiner, M., Pierce, M., & Pande, A. C. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199512000-00007 · Cited by 79

The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats

Shimazaki, T., Iijima, M., & Chaki, S. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.032 · Cited by 78

Injections of urocortin 1 into the basolateral amygdala induce anxiety-like behavior and c-Fos expression in brainstem serotonergic neurons

Spiga, F., Lightman, S. L., Shekhar, A., & Lowry, C. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.12.051 · Cited by 75

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients

van Megen, H. J. G. M., Westenberg, H. G. M., den Boer, J. A., Slaap, B. R., Radhakishun, F. S., & Pande, A. C. (1997) · Psychopharmacology · doi:10.1007/s002130050186 · Cited by 75

The vasopressin V1b receptor as a therapeutic target in stress-related disorders

Griebel, G., Simiand, J., Stemmelin, J., Gal, C., & Steinberg, R. (2003) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007033482850 · Cited by 74

‘Anxiolytic’ effect of CCK-antagonists on plus-maze behavior in mice

Rataud, J., Darche, F., Piot, O., Stutzmann, J. M., Böhme, G. A., & Blanchard, J. (1991) · Brain Research · doi:10.1016/0006-8993(91)91139-r · Cited by 73

Ultrasonic vocalizations in rat pups: modulation at the gamma-aminobutyric acidA receptor complex and the neurosteroid recognition site.

Vivian, J. A., Barros, H. M. T., Manitiu, A., & Miczek, K. A. (1997) · PubMed · Cited by 71

Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior

Bleickardt, C. J., Mullins, D. E., MacSweeney, C. P., Werner, B. J., Pond, A. J., Guzzi, M. F., Martin, F. D. C., Varty, G. B., & Hodgson, R. A. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1354-x · Cited by 71

Ultrasonic Vocalizations In Rat Pups: Modulation at the γ-Aminobutyric AcidA Receptor Complex and the Neurosteroid Recognition Site,

Vivian, J. A., Barros, H. M. T., Manitiu, A., & Miczek, K. A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36770-9 · Cited by 71

Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat

Dableh, L. J., Yashpal, K., Rochford, J. M., & Henry, J. L. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.11.024 · Cited by 70

NKP608, an NK1 receptor antagonist, has an anxiolytic action in the social interaction test in rats

File, S. E. (2000) · Psychopharmacology · doi:10.1007/s002130000513 · Cited by 70

Galanin Receptor Antagonists

Ögren, S. O., Kuteeva, E., kfelt, T. H., & Kehr, J. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00003 · Cited by 68

A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests

Barr, A. M., Kinney, J. W., Hill, M. N., Lü, X., Biros, S. M., REBEK, J. J., & Bartfai, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.06.033 · Cited by 68

Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats.

Kask, A., Rägo, L., & Harro, J. (1998) · Regulatory Peptides · doi:10.1016/s0167-0115(98)00076-7 · Cited by 67

Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant‐like effect via Y1 receptor

Ishida, H., Shirayama, Y., Iwata, M., Katayama, S., Yamamoto, A., Kawahara, R., & Nakagome, K. (2007) · Hippocampus · doi:10.1002/hipo.20264 · Cited by 67

Galanin – 25 years with a multitalented neuropeptide

Hökfelt, T. G. M., & Tatemoto, K. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8152-9 · Cited by 65

Cloning and characterization of teneurin C-terminus associated peptide (TCAP)-3 from the hypothalamus of an adult rainbow trout (Oncorhynchus mykiss)

Qian, X., Baršytė-Lovejoy, D., Wang, L., Chewpoy, B., Gautam, N., Chawaf, A. A., & Lovejoy, D. A. (2004) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2004.02.007 · Cited by 64

Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect

Fendt, M., Bürki, H., Imobersteg, S., Lingenhöhl, K., McAllister, K. H., Orain, D., Uzunov, D. P., & Chaperon, F. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1610-8 · Cited by 61

Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice.

Yamano, M., Yuki, H., Yasuda, S., & Miyata, K. (2000) · PubMed · Cited by 58

Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist

Ballard, T. M., Sänger, S., & Higgins, G. A. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00724-5 · Cited by 58

Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat

Overstreet, D. H., & Griebel, G. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.07.021 · Cited by 58

Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat

Kuteeva, E., Wardi, T., Hökfelt, T. G. M., & Ögren, S. O. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.03.003 · Cited by 57

Teneurin C-terminal associated peptides: An enigmatic family of neuropeptides with structural similarity to the corticotropin-releasing factor and calcitonin families of peptides

Lovejoy, D. A., Chawaf, A. A., & Cadinouche, M. Z. A. (2006) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2006.01.012 · Cited by 57

Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon

Rajarao, S. J. R., Platt, B. J., Rizzo, S. J. S., Lin, Q., Bender, C. N., Nieuwenhuijsen, B. W., Ring, R. H., Schechter, L. E., Rosenzweig-Lipson, S. J., & Beyer, C. E. (2007) · Neuropeptides · doi:10.1016/j.npep.2007.05.001 · Cited by 56

The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice

Hernando, F., Fuentes, J., Roques, B. P., & Ruiz‐Gayo, M. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90115-5 · Cited by 55

Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role?

Mathé, A. A., Husum, H., Khoury, A. E., Jiménez-Vasquez, P. A., Gruber, S. H. M., Wörtwein, G., Nikisch, G., Baumann, P., Ågren, H., Andersson, W., et al. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.016 · Cited by 55

Regulation of neurite growth in immortalized mouse hypothalamic neurons and rat hippocampal primary cultures by teneurin C-terminal-associated peptide-1

Chawaf, A. A., Amant, K. S., Belsham, D. D., & Lovejoy, D. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.09.062 · Cited by 54

Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder

Pande, A. C., Greiner, M., Adams, J. B., Lydiard, R. B., & Pierce, M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00090-6 · Cited by 54

Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats

Cassella, J. V., & Davis, M. (1985) · Psychopharmacology · doi:10.1007/bf00432707 · Cited by 52

Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments

Simon, N. G., Guillon, C., Fabio, K. M., Heindel, N. D., Lu, S., Miller, M., Ferris, C. F., Brownstein, M., Garippa, C., & KOPPEL, G. A. (2008) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488908784534586 · Cited by 52

Antidepressant-Like Effect of Endomorphin-1 and Endomorphin-2 in Mice

Fichna, J., Janecka, A. E., Piestrzeniewicz, M. K., Costentin, J., & do-Rego, J.-C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301149 · Cited by 51

Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test

Chenu, F., Guiard, B. P., Bourin, M., & Gardier, A. M. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.05.011 · Cited by 51

Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modified forced swimming test in mice

Tanaka, M., & Telegdy, G. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2007.08.009 · Cited by 50

Corticotropin-releasing factor type-1 receptor antagonists: The next class of antidepressants?

Nielsen, D. M. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.06.003 · Cited by 50

Neurohypophyseal hormones and brain neurochemistry

Versteeg, D. H. G. (1982) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(82)90071-7 · Cited by 50

Corticotropin-releasing factor (CRF)-induced behaviors are modulated by intravenous administration of teneurin C-terminal associated peptide-1 (TCAP-1)

Chawaf, A. A., Xu, K. H., Tan, L. A., Vaccarino, F. J., Lovejoy, D. A., & Rotzinger, S. (2007) · Peptides · doi:10.1016/j.peptides.2007.05.014 · Cited by 49

From MIF-1 to endomorphin: The Tyr-MIF-1 family of peptides

Pan, W., & Kastin, A. J. (2007) · Peptides · doi:10.1016/j.peptides.2007.10.006 · Cited by 47

Alpha-melanocyte stimulating hormone antagonizes antidepressant-like effect of neuropeptide Y in Porsolt's test in rats

Goyal, S. N., Kokare, D. M., Ct, C., & Subhedar, N. K. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.09.004 · Cited by 46

Modulary effects of oxytocin and carbetocin on stress-induced changes in rat behavior in the open-field.

Klenerová, V., Krejčı́, I., Sida, P., Hlinak, Z., & Hynie, S. (2009) · PubMed · Cited by 46

Induction of NGFI-B mRNA following contextual fear conditioning and its blockade by diazepam

Malkani, S., & Rosen, J. B. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00130-3 · Cited by 42

Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness

VELDE, C. D. V. D. (1983) · Peptides · doi:10.1016/0196-9781(83)90136-5 · Cited by 42

CCK B antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze

Wilson, J., Watson, W. P., & Little, H. J. (1998) · Psychopharmacology · doi:10.1007/s002130050601 · Cited by 41

Improvement in major depression after low subcutaneous doses of MIF-1

Ehrensing, R. H., Kastin, A. J., Wurzlow, G. F., Michell, G. F., & Mebane, A. H. (1994) · Journal of Affective Disorders · doi:10.1016/0165-0327(94)90098-1 · Cited by 41

The Effects of Psychological Stress on Depression

Yang, L., Zhao, Y., Wang, Y., Liu, L., Zhang, X., Li, B., & Cui, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x1304150831150507 · Cited by 589

Breaking the loop: Oxytocin as a potential treatment for drug addiction

McGregor, I. S., & Bowen, M. T. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.12.001 · Cited by 268

The Role of Oxytocin in Psychiatric Disorders: A Review of Biological and Therapeutic Research Findings

Cochran, D. M., Fallon, D., Hill, M., & Frazier, J. A. (2013) · Harvard Review of Psychiatry · doi:10.1097/hrp.0b013e3182a75b7d · Cited by 267

Stress, Endocrine Physiology and Pathophysiology -- Endotext

DeGroot, L. J., Chrousos, G. P., Dungan, K., Grossman, A. B., Jm, H., Koch, C., Korbonits, M., McLachlan, R., New, M., Purnell, J. Q., et al. (2000) · Europe PMC (PubMed Central) · Cited by 260

Comparative Analyses of Zebrafish Anxiety-Like Behavior Using Conflict-Based Novelty Tests

Kysil, E. V., Мешалкина, Д. А., Frick, E. E., Echevarria, D. J., Rosemberg, D. B., Maximino, C., Lima, M. G., de Abreu, M. S., Giacomini, A. C. V. V., Barcellos, L. J. G., et al. (2017) · Zebrafish · doi:10.1089/zeb.2016.1415 · Cited by 277

Neurohypophyseal hormones and brain neurochemistry

Versteeg, D. H. G. (1982) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(82)90071-7 · Cited by 50

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

Holmes, A., Heilig, M. A., Rupniak, N. M. J., Steckler, T., & Griebel, G. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.09.011 · Cited by 405

Role of neuropeptides in anxiety, stress, and depression: From animals to humans

Kormos, V., & Gaszner, B. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.014 · Cited by 333

Neuropeptides as Therapeutic Targets in Anxiety Disorders

Lin, E.-J. D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803530871 · Cited by 28

Exploring the role of neuropeptides in depression and anxiety

Rana, T., Behl, T., Sehgal, A., Singh, S., Sharma, N., Abdeen, A., Ibrahim, S. F., Mani, V., Iqbal, M. S., Bhatia, S., et al. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110478 · Cited by 128